EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY 4.0

Localized high-risk prostate cancer harbors an androgen receptor activity–low subpopulation susceptible to HER2 inhibition

Scott Wilkinson, Anson T Ku, Rosina T Lis, Isaiah M King, Daniel Low, Shana Y Trostel, John R Bright, Nicholas T Terrigino, Anna Baj, Emily R Summerbell, Kayla E Heyward, Sumeyra Kartal und 19 weitere

Journal of Clinical Investigation · 2025

DOI: 10.1172/jci189900 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Scott Wilkinson und 30 weiteren Autor:innen. Beteiligte Einrichtung: Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Neoplasm Proteins, Prostatic Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Receptors, Androgen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, Intramural NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasm ProteinsProstatic NeoplasmsErb-b2 Receptor Tyrosine KinasesReceptors, AndrogenAgedHumansMaleMiddle AgedAndrogen AntagonistsBenzamidesNitrilesPhenylthiohydantoinProstatectomyPTEN Phosphohydrolase

Stichwörter der Autor:innen

GeneticsMolecular pathologyOncogenesOncologyProstate cancer

Substanzen

Androgen AntagonistsBenzamidesNeoplasm ProteinsNitrilesPhenylthiohydantoinPTEN PhosphohydrolaseErb-b2 Receptor Tyrosine KinasesReceptors, AndrogenAR protein, humanenzalutamide

Autor:innen und Institutionen

  • Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.
  • Office of Intramural Research, National Institutes of Health, Bethesda, Maryland, USA.
  • Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA.
  • Department of Urology, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Department of Pathology and Department of Urology, UCLA, Los Angeles, California, USA.
  • Molecular Imaging Branch.

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS
  • Intramural NIH HHS
  • DOD Prostate Cancer Research Program
  • National Institutes of Health
  • Prostate Cancer Foundation
  • Intramural Research Program, National Cancer Institute

Zitieren

APA

Wilkinson, S., Ku, A. T., Lis, R. T., King, I. M., Low, D., Trostel, S. Y., Bright, J. R., Terrigino, N. T., Baj, A., Summerbell, E. R., Heyward, K. E., Kartal, S., Fenimore, J. M., Li, C., Singler, C., Vo, B., Jansen, C. S., Ye, H., Whitlock, N. C., …, & Sowalsky, A. G. (2025). Localized high-risk prostate cancer harbors an androgen receptor activity–low subpopulation susceptible to HER2 inhibition. Journal of Clinical Investigation. https://doi.org/10.1172/jci189900

Vancouver

Wilkinson S, Ku AT, Lis RT, King IM, Low D, Trostel SY, et al. Localized high-risk prostate cancer harbors an androgen receptor activity–low subpopulation susceptible to HER2 inhibition. Journal of Clinical Investigation. 2025. doi:10.1172/jci189900

BibTeX
@article{Wilkinson2025,
  author = {Wilkinson, Scott and Ku, Anson T and Lis, Rosina T and King, Isaiah M and Low, Daniel and Trostel, Shana Y and Bright, John R and Terrigino, Nicholas T and Baj, Anna and Summerbell, Emily R and Heyward, Kayla E and Kartal, Sumeyra and Fenimore, John M and Li, Chennan and Singler, Cassandra and Vo, BaoHan and Jansen, Caroline S and Ye, Huihui and Whitlock, Nichelle C and Harmon, Stephanie A and Carrabba, Nicole V and Atway, Rayann and Lake, Ross and Takeda, David Y and Kissick, Haydn T and Pinto, Peter A and Choyke, Peter L and Turkbey, Baris and Dahut, William L and Karzai, Fatima and Sowalsky, Adam G},
  title = {Localized high-risk prostate cancer harbors an androgen receptor activity–low subpopulation susceptible to HER2 inhibition},
  journal = {Journal of Clinical Investigation},
  year = {2025},
  doi = {10.1172/jci189900}
}
Kostenlos starten →